Skip to main content

Table 1 Clinical characteristics of eyes treated with PDT

From: Transient accumulation of subretinal fluid after half-fluence photodynamic therapy in neovascular age-related macular degeneration

Included eye Patient characteristics Lesion type Pre-PDT BCVA (logMAR) Disease duration (months) Previous PDT sessions(n) Previous anti-VEGF injections (n) Pre-PDT RPE atrophy Treatment methods Spot size (μm)
Age (years) Sex DM HTN
1 81 M Y N CNV 1.00 132 1 8 Y PDT + IVB 5900
2 52 F N N CNV 0.80 1 0 0 Y PDT + IVB 3500
3 82 F N N CNV 0.92 108 4 1 Y PDT + Dexamethasone + IVB 3600
4 66 M Y Y PCV 0.49 16 2 3 Y PDT + Dexamethasone + IVB 3700
5 84 M N N CNV 0.49 48 5 7 Y PDT + Dexamethasone + IVB 2900
6 79 F N Y RAP 0.80 1 0 1 Y PDT + Dexamethasone + IVB 4500
7 78 F N Y PCV 1.30 20 2 7 N PDT + IVB 5800
8 60 F N N CNV 0.10 68 6 3 Y PDT + IVB 4100
9 75 F N N PCV 1.30 21 2 1 N PDT + Dexamethasone + IVB 4900
10 73 M Y Y PCV 0.30 18 1 1 N PDT + Dexamethasone + IVB 5200
11 71 M N Y PCV 1.30 48 3 1 Y PDT + IVB 6400
12 65 M N N CNV 0.80 8 0 1 N PDT 5050
13 60 M N N CNV 0.49 19 3 11 N PDT + IVR 1900
14 68 F N N RAP 0.00 12 1 1 Y PDT + IVB 1400
15 62 M N Y CNV 0.80 9 1 2 N PDT + Dexamethasone + IVB 3200
16 64 M N Y CNV 0.80 26 4 9 N PDT + IVB 2700
17 52 M N N CNV 0.20 4 1 1 Y PDT + Dexamethasone + IVB 3200
18 28 M N N CNV N/A 1 0 1 Y PDT + IVB 2600
19 50 F N N PCV 0.00 1 0 0 N PDT + IVR 4800
20 34 M N N CNV 0.10 11 0 3 N PDT 1900
21 67 M N N PCV 0.70 8 0 9 N PDT + IVB 3700
22 69 M N N PCV 0.52 22 1 14 N PDT 4000
23 74 M N N PCV 0.52 17 0 14 N PDT 1500
24 70 F N N PCV 0.52 14 0 6 N PDT 2800
25 70 F N N PCV 0.82 14 0 8 N PDT 3300
26 74 F Y Y PCV 0.70 60 0 9 N PDT 3700
27 67 F N N CNV 0.10 24 0 9 N PDT 2500
28 77 M N N PCV 0.00 30 0 16 N PDT 1500
29 77 M N N CNV 0.70 3 0 10 N PDT 4200
  1. BCVA best-corrected visual acuity, CNV choroidal neovascularisation, DM diabetes mellitus, F female, HTN hypertension, IVB intravitreal injection of bevacizumab, IVR intravitreal injection of ranibizumab, logMAR logarithm of the minimum angle of resolution, M male, N no, N/A not accessed, PCV polypoidal choroidal vasculopathy, PDT photodynamic therapy, RAP retinal angiomatous proliferation, RPE retinal pigment epithelium, VEGF vascular endothelial growth factor, Y yes
\